Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - November 5, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan) is pleased to announce that all
Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - October 28, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that
Innocan Pharma Corporation: Innocan Pharma s CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(3)
Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - August 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the Company or Innocan ), is pleased to issue an update on its cutting-edge pre-clinical studies and on the development progress of its Liposome/CBD delivery platform (LPT). These studies are led by Dr. Ahuva Cern and Prof. Chezy Barenholz of The Hebrew University of Jerusalem.
To date, Innocan completed two pre-clinical trials on animals. The first trial demonstrated no side effects, while the duration of a single intra-muscular injection resulted in the presence of a high level of CBD for at least 3 weeks in the plasma. In the second trial, the researchers observed the effect of CBD in a disease model of the central nervous system, while CBD was detected for a period of over 7 weeks, after 2 injections.
Herzliya, Israel and Calgary Alberta (Newsfile Corp. - June 11, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that a recent